Evidence map›Paper›PMID 39951277›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2025

DNA Origami-Cyanine Nanocomplex for Precision Imaging of KRAS-Mutant Pancreatic Cancer Cells.

Hye-Ran Moon, Yancheng Du, Sae Rome Choi, Seongmin Seo, Cih Cheng, Bennett D Elzey, Jong Hyun Choi, Bumsoo Han

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Function ofOncology letters · 2025
    Review
  4. DNA Origami-Cyanine Nanocomplex for Precision Imaging of KRAS-Mutant Pancreatic Cancer Cells.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Hye-Ran MoonSchool of Mechanical Engineering, Purdue University, West Lafayette, IN, 47907, USA.
Yancheng DuSchool of Mechanical Engineering, Purdue University, West Lafayette, IN, 47907, USA.
Sae Rome ChoiSchool of Mechanical Engineering, Purdue University, West Lafayette, IN, 47907, USA.
Seongmin SeoSchool of Mechanical Engineering, Purdue University, West Lafayette, IN, 47907, USA.
Cih ChengSchool of Mechanical Engineering, Purdue University, West Lafayette, IN, 47907, USA.
Bennett D ElzeyPurdue Institute for Cancer Research, Purdue University, West Lafayette, IN, 47907, USA.
Jong Hyun ChoiSchool of Mechanical Engineering, Purdue University, West Lafayette, IN, 47907, USA.
Bumsoo HanSchool of Mechanical Engineering, Purdue University, West Lafayette, IN, 47907, USA.ORCID https://orcid.org/0000-0001-9487-1090

Funding

Transgenic Mouse Core Facility Shared Resource (TMCF-SR)P30CA023168 · NCI · PURDUE UNIVERSITY WEST LAFAYETTE · PI ANDREW D MESECAR · 1985 to 2026
$43.4M
Indiana Clinical and Translational Sciences InstituteUM1TR004402 · NCATS · INDIANA UNIVERSITY INDIANAPOLIS · PI Sharon M Moe, Sarah Elizabeth Wiehe · 2023 to 2026
$21.6M
Reprogramming PDAC Stroma by Targeting Coagulation in the Tumor MicroenvironmentU01CA274304 · NCI · UNIVERSITY OF ILLINOIS AT URBANA-CHAMPAIGN · PI Melissa L. Fishel, Matthew J. Flick · 2022 to 2026
$4.6M
Targeting the Plasminogen Activation System to Limit Pancreatic Cancer Progression and Associated ThrombosisU01HL143403 · NHLBI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI FISHEL, MELISSA L., FLICK, MATTHEW J. · 2018 to 2022
$4.2M
Investigation of novel signaling protein in 3D and in vivo PDAC models using second generation Ref-1 inhibitorsR01CA254110 · NCI · INDIANA UNIVERSITY INDIANAPOLIS · PI FISHEL, MELISSA L., HAN, BUMSOO · 2021 to 2025
$2.1M
National Science Foundation MCB-2134603NCATS NIH HHS UM1 TR004402NCI NIH HHS P30 CA023168NCI NIH HHS R01 CA254110NCI NIH HHS U01 CA274304NHLBI NIH HHS U01 HL143403NIH HHS P30CA023168NIH HHS R01CA254110NIH HHS U01CA274304NIH HHS U01HL143403NIH HHS UM1TR004402
6 · The paper itself

Abstract

Selective delivery of imaging agents to pancreatic cancer cells (PCCs) within the highly desmoplastic tumors of pancreatic ductal adenocarcinoma (PDAC) represents a significant advancement. This approach allows for precise labeling of PCCs while excluding cancer-associated fibroblasts (CAFs), thereby enhancing both research and diagnostic capabilities. Additionally, it holds the potential to target and eliminate PCCs precisely without harming the surrounding stromal cells in the PDAC tumor microenvironment (TME). In this study, DNA origami-cyanine (Do-Cy) nanocomplexes are synthesized to image KRAS-mutant PCCs selectively in the PDAC TME. These Do-Cy nanocomplexes are hypothesized to be internalized preferentially to KRAS-mutant PCCs over CAFs via elevated macropinocytosis. Several designs of Do-Cy nanocomplexes are synthesized and characterized their cellular uptake using both engineered in vitro and xenograft pancreatic cancer models. The results are further discussed for the implication of precision delivery of therapeutic and imaging agents to KRAS-mutant cancers.

Indexed as

CarbocyaninesCarcinoma, Pancreatic DuctalDNAPancreatic NeoplasmsProto-Oncogene Proteins p21(ras)AnimalsCell Line, TumorHumansMiceMutationTumor MicroenvironmentCarbocyaninesDNAKRAS protein, humanProto-Oncogene Proteins p21(ras)DNA origamiKRAS mutationmacropinocytosismicrofluidic tumor modelnanoparticle deliverystroma tissue

Identifiers

PMID39951277
PMCPMC12097083

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.